Premium
Second‐ and third‐trimester serum levels of growth‐differentiation factor‐15 in prediction of pre‐eclampsia
Author(s) -
Wertaschnigg D.,
Rolnik D. L.,
Nie G.,
Teoh S. S. Y.,
Syngelaki A.,
da Silva Costa F.,
Nicolaides K. H.
Publication year - 2020
Publication title -
ultrasound in obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.202
H-Index - 141
eISSN - 1469-0705
pISSN - 0960-7692
DOI - 10.1002/uog.22070
Subject(s) - medicine , gestation , gdf15 , asymptomatic , obstetrics , gestational age , eclampsia , pregnancy , preeclampsia , genetics , biology
Objective Pre‐eclampsia (PE) is a significant contributor to adverse maternal and perinatal outcome; however, accurate prediction and early diagnosis of this condition remain a challenge. The aim of this study was to compare serum levels of growth‐differentiation factor‐15 (GDF‐15) at three different gestational ages between asymptomatic women who subsequently developed preterm or term PE and healthy controls. Methods This was a case–control study drawn from a prospective observational study on adverse pregnancy outcomes in women attending for their routine second‐ and third‐trimester hospital visits. Serum GDF‐15 was determined in 300 samples using a commercial GDF‐15 enzyme‐linked immunosorbent assay: 120 samples at 19–24 weeks of gestation, 120 samples at 30–34 weeks and 60 samples at 35–37 weeks. Multiple linear regression was applied to logarithmically transformed GDF‐15 control values to evaluate the influence of gestational age at blood sampling and maternal characteristics on GDF‐15 results. GDF‐15 multiples of the normal median (MoM) values, adjusted for gestational age and maternal characteristics, were compared between pregnancies that subsequently developed preterm or term PE and healthy controls. Results Values of GDF‐15 increased with gestational age. There were no significant differences in GDF‐15 MoM values between cases of preterm or term PE and normotensive pregnancies at 19–24 or 35–37 weeks of gestation. At 30–34 weeks, GDF‐15 MoM values were significantly increased in cases of preterm PE, but not in those who later developed term PE. Elevated GDF‐15 MoM values were associated significantly with a shorter interval between sampling at 30–34 weeks and delivery with PE ( P = 0.005). Conclusion Serum GDF‐15 levels at 19–24 or 35–37 weeks of gestation are not predictive of preterm or term PE. At 30–34 weeks, GDF‐15 levels are higher in women who subsequently develop preterm PE; however, this difference is small and GDF‐15 is unlikely to be useful in clinical practice when used in isolation. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.